Alan Huang - Aug 10, 2021 Form 3 Insider Report for Tango Therapeutics, Inc. (TNGX)

Role
Chief Scientific Officer
Signature
By: /s/ Daniella Beckman, as attorney-in-fact
Stock symbol
TNGX
Transactions as of
Aug 10, 2021
Transactions value $
$0
Form type
3
Date filed
8/12/2021, 08:36 PM
Next filing
Aug 16, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding TNGX Common Stock 136K Aug 10, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TNGX Stock Option (Right to Buy) Aug 10, 2021 Common Stock 84.9K $1.38 Direct F1
holding TNGX Stock Option (Right to Buy) Aug 10, 2021 Common Stock 110K $1.38 Direct F2
holding TNGX Stock Option (Right to Buy) Aug 10, 2021 Common Stock 67.9K $1.53 Direct F3
holding TNGX Stock Option (Right to Buy) Aug 10, 2021 Common Stock 67.9K $1.65 Direct F4
holding TNGX Stock Option (Right to Buy) Aug 10, 2021 Common Stock 95.1K $3.50 Direct F5
holding TNGX Stock Option (Right to Buy) Aug 10, 2021 Common Stock 67.9K $3.50 Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option shall vest and become exercisable in equally monthly installments over a period of 48 months from January 1, 2018.
F2 This option shall vest and become exercisable in monthly installments over a period of 48 months from April 1, 2018.
F3 This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2020, with the remaining option shares vesting in 36 equal monthly installments thereafter.
F4 This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2021, with the remaining option shares vesting in 36 equal monthly installments thereafter.
F5 This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter.
F6 This option shall vest and become exercisable over a four-year period, at a rate of 25% on January 1, 2022, with the remaining option shares vesting in 36 equal monthly installments thereafter.

Remarks:

Exhibit 24: Power of Attorney